PlumX Metrics
Embed PlumX Metrics

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma

Nature Medicine, ISSN: 1546-170X, Vol: 28, Issue: 12, Page: 2592-2600
2022
  • 32
    Citations
  • 0
    Usage
  • 80
    Captures
  • 0
    Mentions
  • 3
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Treatment with immune checkpoint blockade (ICB) frequently triggers immune-related adverse events (irAEs), causing considerable morbidity. In 214 patients receiving ICB for melanoma, we observed increased severe irAE risk in minor allele carriers of rs16906115, intronic to IL7. We found that rs16906115 forms a B cell-specific expression quantitative trait locus (eQTL) to IL7 in patients. Patients carrying the risk allele demonstrate increased pre-treatment B cell IL7 expression, which independently associates with irAE risk, divergent immunoglobulin expression and more B cell receptor mutations. Consistent with the role of IL-7 in T cell development, risk allele carriers have distinct ICB-induced CD8 T cell subset responses, skewing of T cell clonality and greater proportional repertoire occupancy by large clones. Finally, analysis of TCGA data suggests that risk allele carriers independently have improved melanoma survival. These observations highlight key roles for B cells and IL-7 in both ICB response and toxicity and clinical outcomes in melanoma.

Bibliographic Details

Taylor, Chelsea A; Watson, Robert A; Tong, Orion; Ye, Weiyu; Nassiri, Isar; Gilchrist, James J; de Los Aires, Alba Verge; Sharma, Piyush Kumar; Koturan, Surya; Cooper, Rosalin A; Woodcock, Victoria K; Jungkurth, Elsita; Shine, Brian; Coupe, Nicholas; Payne, Miranda J; Church, David N; Naranbhai, Vivek; Groha, Stefan; Emery, Paul; Mankia, Kulveer; Freedman, Matthew L; Choueiri, Toni K; Middleton, Mark R; Gusev, Alexander; Fairfax, Benjamin P

Springer Science and Business Media LLC

Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know